- Home
- SGD vs XBIO Comparison
SGD vs XBIO Comparison
Compare SGD & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGD
- XBIO
- Stock Information
- Founded
- SGD 2021
- XBIO N/A
- Country
- SGD United States
- XBIO United States
- Employees
- SGD N/A
- XBIO N/A
- Industry
- SGD
- XBIO Biotechnology: Pharmaceutical Preparations
- Sector
- SGD
- XBIO Health Care
- Exchange
- SGD Nasdaq
- XBIO Nasdaq
- Market Cap
- SGD 4.4M
- XBIO 4.4M
- IPO Year
- SGD N/A
- XBIO N/A
- Fundamental
- Price
- SGD $1.35
- XBIO $3.56
- Analyst Decision
- SGD
- XBIO Hold
- Analyst Count
- SGD 0
- XBIO 1
- Target Price
- SGD N/A
- XBIO N/A
- AVG Volume (30 Days)
- SGD 1.4M
- XBIO 12.3K
- Earning Date
- SGD 08-15-2025
- XBIO 11-11-2025
- Dividend Yield
- SGD N/A
- XBIO N/A
- EPS Growth
- SGD N/A
- XBIO N/A
- EPS
- SGD N/A
- XBIO N/A
- Revenue
- SGD $1,536,255.00
- XBIO $2,446,221.00
- Revenue This Year
- SGD N/A
- XBIO $1.99
- Revenue Next Year
- SGD N/A
- XBIO $20.00
- P/E Ratio
- SGD N/A
- XBIO N/A
- Revenue Growth
- SGD 1570.24
- XBIO N/A
- 52 Week Low
- SGD $0.65
- XBIO $2.20
- 52 Week High
- SGD $6.25
- XBIO $5.27
- Technical
- Relative Strength Index (RSI)
- SGD 55.71
- XBIO 67.72
- Support Level
- SGD $1.02
- XBIO $2.97
- Resistance Level
- SGD $1.80
- XBIO $3.15
- Average True Range (ATR)
- SGD 0.15
- XBIO 0.21
- MACD
- SGD 0.03
- XBIO 0.07
- Stochastic Oscillator
- SGD 52.63
- XBIO 87.22
About SGD Safe and Green Development Corporation
Safe & Green Development Corp is a real estate development company that focuses on the development of sites using purpose built, prefabricated modules built from both wood & steel, sourced from one of Safe and Green Holdings factories. The company's business model is flexible and it anticipates developing properties on its own and also through joint ventures in which it partners with third-party equity investors or other developers.
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.